Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
TAIPEI, Taiwan and SAN DIEGO, Nov. 1, 2018 /PRNewswire/ — Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC). To…